本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： | 权益变动方向 | 比例增加□ | | 比例减少☑ | | --- | --- | --- | --- | | 权益变动前合计比例 | 61.56% | | | | 权益变动后合计比例 | 60.85% | | | | 本次变动是否违反已作出的承 诺、意向、计划 | 是□ | 否☑ | | | 是否触发强制要约收购义务 | 是□ | 否☑ | | 一、 信息披露义务人及其一致行动人的基本信息 证券代码：603567 证券简称：珍宝岛 公告编号：临2025-057 黑龙江珍宝岛药业股份有限公司 关于控股股东权益变动触及 1%刻度的提示性公告 黑龙江创达集团有限公司保证向本公司提供的信息真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 1.身份类别 | | ☑控股股东/实际控制人及其一致行动人 □其他 5%以上大股东及其一致行动人 | | --- | --- | | 投资者及其一致行动人的身份 | □合并口径第一大股东及其一致行动人（仅适 | | | 用于无控股股东、实际控制人） | | | □其他___________ ...

Group 1 - The report highlights the resilience of the overseas economy, tariff developments, and expectations for a rate cut in September, with a focus on technology growth and opportunities for clearing internal competition in the domestic market [4][14][18] - The A-share market is expected to challenge last year's highs, with a strong focus on technology growth and sectors that can benefit from the reduction of internal competition, such as steel, coal, cement, glass, photovoltaic, new energy vehicles, and live pigs [21][4] - The report recommends a diversified portfolio of stocks, including companies in electronics, new energy, power equipment, non-ferrous metals, chemicals, and pharmaceuticals, with specific companies highlighted as top picks [5][12][22] Group 2 - The electronics sector is represented by companies like Zhongji Xuchuang, which is expected to see significant profit growth due to increased demand for high-speed optical modules driven by AI infrastructure [22][23] - The semiconductor industry is recovering, with Tongfu Microelectronics reporting a notable increase in revenue and profit, driven by the resurgence in the consumer electronics market [31][33] - The new energy sector, represented by Qiangrui Technology, is experiencing rapid growth in smart automotive and AI server equipment, indicating strong future growth potential [37][39] Group 3 - The power equipment sector, represented by Xinshi Da, is focusing on industrial automation and robotics, with a strong market position in elevator control systems and a growing presence in the robotics industry [43][44] - The non-ferrous metals sector, represented by Xingye Yinxin, is benefiting from rising prices of silver and tin, with significant production increases and strategic acquisitions to enhance future growth [49][51][54]

Investment Rating - The report assigns a "Buy" rating for the company, marking it as the first recommendation [1]. Core Insights - The company is expected to face short-term impacts from centralized procurement, but sales are anticipated to improve post-implementation. The net profit for the first half of 2025 is projected to be between -77 million and -66 million yuan, primarily due to delayed procurement timelines and price reductions on core products, leading to a 57% decline in revenue and a 64% drop in gross profit year-on-year [3][4]. - The company has made significant progress in the development of innovative traditional Chinese medicine, with a key milestone achieved in the clinical trial of Qingjiang Hewei Granules, which targets a complex syndrome of non-erosive gastroesophageal reflux disease [5]. - The company holds a 17.0211% stake in Zhejiang Tereis, which is developing a first-in-class ADC product, TRS005, showing promising clinical results for treating relapsed or refractory CD20-positive diffuse large B-cell lymphoma [6][7]. Summary by Sections Financial Performance - The company is expected to see a revenue decline in 2025, with projections of 1.984 billion yuan, followed by a recovery to 2.823 billion yuan in 2026 and 3.066 billion yuan in 2027. The earnings per share (EPS) are forecasted to be 0.07 yuan in 2025, 0.50 yuan in 2026, and 0.54 yuan in 2027, with corresponding price-to-earnings (P/E) ratios of 185.9, 24.8, and 23 respectively [8][10]. Market Position and Growth Drivers - The company’s core products are expected to regain sales momentum following the implementation of centralized procurement, which is anticipated to positively impact revenue in the latter half of 2025 [4]. - The innovative drug development and the ADC platform are seen as potential growth drivers for the company, with the ADC product expected to receive regulatory approval in 2024 [6][8]. Investment Outlook - The report suggests that despite short-term challenges due to procurement policies, the company’s innovative drug pipeline and strategic partnerships could lead to significant growth in the coming years, justifying the "Buy" rating [8].

Group 1 - The A-share innovative drug concept stocks continue to rise, with Nanxin Pharmaceutical hitting the 20% daily limit up [1] - Qizheng Tibetan Medicine and Hanshang Group also reached the daily limit up, indicating strong market interest [1] - Other companies such as Hitec Biological, Anke Biological, Huisheng Biological, Zhendong Pharmaceutical, Tebao Biological, and Treasure Island saw increases of over 5% [1]

（文章来源：每日经济新闻） 每经AI快讯，7月31日，创新药概念股持续活跃，南新制药20%涨停，奇正藏药、汉商集团涨停，海特 生物、安科生物、回盛生物、振东制药、特宝生物、珍宝岛等涨超5%。 ...

Group 1 - The A-share innovative drug concept stocks continue to rise, with Nanjing New Pharmaceutical hitting the 20% daily limit up [1] - Qizheng Pharmaceutical and Hanchang Group also reached the daily limit up [1] - Other companies such as Hite Bio, Anke Bio, Huisheng Bio, Zhendong Pharmaceutical, Tebao Bio, and Zhenbaodao saw increases of over 5% [1]

Group 1 - The core viewpoint of the news is that Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. has experienced significant declines in revenue and net profit in its latest quarterly report, indicating potential challenges for the company [1] - As of July 29, 2025, Zhenbaodao's stock closed at 12.4 yuan, down 2.21%, with a trading volume of 182,700 hands and a transaction amount of 227 million yuan [1] - The company's latest quarterly report shows total operating revenue of 469 million yuan, a year-on-year decrease of 58.03%, and a net profit attributable to shareholders of 75.3 million yuan, a year-on-year decrease of 74.33% [1] Group 2 - The company has a current ratio of 2.300, a quick ratio of 1.770, and a debt-to-asset ratio of 34.99%, indicating a relatively stable liquidity position [1] - Zhenbaodao has made investments in 27 enterprises and participated in 2,123 bidding projects, showcasing its active engagement in the market [2] - The company holds 133 trademark registrations and 204 patents, along with 229 administrative licenses, reflecting its commitment to intellectual property and regulatory compliance [2]

Market Overview - The Chinese medicine sector rose by 1.0% on July 29, with Foci Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3609.71, up 0.33%, while the Shenzhen Component Index closed at 11289.41, up 0.64% [1] Top Gainers in Chinese Medicine Sector - Foci Pharmaceutical (002644) closed at 10.69, up 9.98% with a trading volume of 841,300 shares and a turnover of 876 million yuan [1] - Zhongsheng Pharmaceutical (002317) also rose by 9.98% to 19.73, with a trading volume of 1,168,400 shares and a turnover of 2.26 billion yuan [1] - Other notable gainers include: - Zhendong Pharmaceutical (300158) up 6.66% to 7.69 [1] - Huasen Pharmaceutical (002907) up 6.50% to 18.51 [1] - Kangjia Pharmaceutical (600557) up 5.61% to 16.58 [1] Top Losers in Chinese Medicine Sector - Qidi Pharmaceutical (000590) fell by 2.65% to 12.13, with a trading volume of 134,500 shares and a turnover of 163 million yuan [2] - Zhenbaodao (603567) decreased by 2.21% to 12.40, with a trading volume of 182,700 shares and a turnover of 227 million yuan [2] - Other notable losers include: - Yunnan Baiyao (000538) down 1.20% to 55.82 [2] - Kangmei Pharmaceutical (600518) down 0.94% to 2.10 [2] Capital Flow Analysis - The Chinese medicine sector saw a net inflow of 798 million yuan from institutional investors, while retail investors experienced a net outflow of 625 million yuan [2][3] - Notable net inflows from institutional investors include: - Zhongsheng Pharmaceutical (002317) with a net inflow of 308 million yuan [3] - Zhendong Pharmaceutical (300158) with a net inflow of 96.32 million yuan [3] - Conversely, significant net outflows from retail investors were observed in: - Zhongsheng Pharmaceutical (002317) with a net outflow of 98.88 million yuan [3] - Zhendong Pharmaceutical (300158) with a net outflow of 65.62 million yuan [3]

Core Viewpoint - The legal opinion letter from Beijing Lantai Law Firm confirms that Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. has complied with necessary legal procedures and disclosure obligations regarding the repurchase and cancellation of part of its restricted stock under the 2023 equity incentive plan [2][9]. Group 1: Decision Process and Disclosure - The company has obtained legal authorization from the board of directors to proceed with the repurchase and cancellation of restricted stocks for three former employees who have not yet lifted their sales restrictions [6]. - The company plans to repurchase a total of 144,094 shares of restricted stock at a price of 8.232 yuan per share, following the approval of relevant proposals by the board and supervisory committee [6][7]. - The company has disclosed the repurchase plan to creditors, allowing them a 30-day period to claim debts or request guarantees, with no claims reported during the disclosure period [6][7]. Group 2: Repurchase Details - The repurchase is due to the departure of three key employees, and the company will buy back the restricted stocks that have not yet been lifted from their restrictions [7]. - The total amount for the repurchase is calculated to be 1,186,181.80 yuan, sourced from the company's own funds [8]. - The company has set up a dedicated securities account for the repurchase and expects to complete the cancellation of the restricted stocks by July 29, 2025 [8].

Core Viewpoint - The company, Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd., is implementing a buyback and cancellation of 144,094 restricted stocks due to the departure of three employees, which represents 5.95% of the total stock under the incentive plan and 0.02% of the company's total share capital [1][2]. Group 1: Buyback and Cancellation Details - The buyback and cancellation are based on the provisions of the "Incentive Plan" and the "Management Measures for Equity Incentives of Listed Companies," which stipulate that restricted stocks cannot be released from restrictions if the employee has left the company [2][3]. - The total amount for the buyback is 1,186,181.80 yuan, sourced from the company's own funds [2][3]. - The cancellation of the stocks is expected to be completed by July 29, 2025, with the company having opened a dedicated securities account for this purpose [3]. Group 2: Impact on Share Capital Structure - Following the cancellation, the company's total share capital will decrease from 941,140,609 shares to 940,996,515 shares [3][4]. - The cancellation will not affect the controlling shareholder or the actual controller, and the company's equity distribution will still meet the listing requirements [4]. Group 3: Legal Compliance and Commitments - The board of directors confirmed that the decision-making process and information disclosure comply with relevant laws and regulations, ensuring no harm to the rights of the incentive objects or creditors [4][5]. - The company has committed to handling any disputes arising from this buyback and cancellation responsibly [4][5].